AKBA Akebia Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1517022 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.4%
TTM net income YoY-180.2%
TTM EPS YoY-112.5%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—
Margins
Gross margin78.9%
Operating margin-15.7%
Net margin-22.6%
FCF margin7.0%
EBITDA margin-15.1%
Returns
ROE-143.8%
ROA-12.6%
ROIC (approx.)—
Asset turnover0.56x
Leverage & solvency
Liabilities / assets94.0%
Debt / equity2.47x
Current ratio1.36x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.35x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $236.20M | $160.18M |
| Cost of revenue | $39.46M | $63.18M |
| Gross profit | $196.73M | $97.00M |
| R&D expense | $62.36M | $37.65M |
| SG&A expense | $107.48M | $106.55M |
| Operating income | $23.50M | -$50.47M |
| Pretax income | -$3.72M | -$69.41M |
| Income tax | $1.62M | $0 |
| Net income | -$5.34M | -$69.41M |
| EBITDA | $24.77M | -$49.01M |
| EPS (basic) | -0.02 | -0.33 |
| EPS (diluted) | -0.02 | -0.33 |
| Weighted avg. shares (diluted) | 257.16M | 210.95M |
| Balance sheet | ||
| Cash & equivalents | $184.84M | $53.55M |
| Receivables | $47.03M | $34.37M |
| Inventory | $15.61M | $16.24M |
| Current assets | $252.96M | $113.83M |
| PP&E, net | $1.22M | $2.20M |
| Goodwill | $59.04M | $59.04M |
| Intangibles | — | $0 |
| Total assets | $376.56M | $220.67M |
| Current liabilities | $162.94M | $80.91M |
| Short-term debt | $0 | $0 |
| Long-term debt | $48.25M | $38.69M |
| Total debt | $48.25M | $38.69M |
| Total liabilities | $343.95M | $269.86M |
| Shareholders' equity | $32.61M | -$49.19M |
| Net debt | -$136.59M | -$14.86M |
| Shares outstanding | 265.42M | 224.85M |
| Cash flow statement | ||
| Operating cash flow | $67.99M | -$40.66M |
| Capital expenditure | $291,000 | $33,000 |
| Free cash flow | $67.70M | -$40.69M |
| Investing cash flow | -$7.93M | -$33,000 |
| Financing cash flow | $72.93M | $49.66M |
| Depreciation & amortization | $1.27M | $1.46M |
| Stock-based compensation | $11.28M | $7.78M |
Free plan shows the latest 2 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.